Tranquilizers or anti-depressants for chronic schizophrenics: a long term study
- PMID: 4053
- DOI: 10.3109/00048677509159857
Tranquilizers or anti-depressants for chronic schizophrenics: a long term study
Abstract
The relative efficacy of 4 tranquilizers was investigated in 66 chronic schizophrenics who had been hospitalized for 10.01 years (mean). The role of adding an anti-depressant was also studied. Following a 4 week placebo period, high dosage tranquilizers were given for 16 weeks and amitriptyline was added for the following 16 weeks. Statistical analyses of the various change measures revealed that patients worsened significantly on placebo, all 4 tranquilizers were significantly better than placebo for symptom reduction and maximum improvement was attained within 16 weeks of tranquilizer administration. No significant differences in efficacy were observed among the 4 tranquilizers and addition of amitriptyline did not confer any additional therapeutic advantage.
Similar articles
-
A double-blind trial of amitriptyline/perphenazine, perphenazine and placebo in chronic withdrawn inert schizophrenics.Br J Psychiatry. 1967 Dec;113(505):1425-9. doi: 10.1192/bjp.113.505.1425. Br J Psychiatry. 1967. PMID: 4865295 Clinical Trial. No abstract available.
-
A controlled clinical trial of amitriptyline added to perphenazine in the treatment of depressed schizophrenics [proceedings].Psychopharmacol Bull. 1979 Apr;15(2):80-1. Psychopharmacol Bull. 1979. PMID: 373008 Clinical Trial. No abstract available.
-
Combined therapy in chronic schizophrenics stabilized on phenothiazine tranquilizers and given BL-KR140 or imipramine or placebo concurrently.Curr Ther Res Clin Exp. 1967 Nov;9(11):576-8. Curr Ther Res Clin Exp. 1967. PMID: 4965507 Clinical Trial. No abstract available.
-
Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.Arch Gen Psychiatry. 2005 Sep;62(9):961-70. doi: 10.1001/archpsyc.62.9.961. Arch Gen Psychiatry. 2005. PMID: 16143728 Review.
-
Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.Int J Clin Pract. 2011 Feb;65(2):189-210. doi: 10.1111/j.1742-1241.2010.02587.x. Epub 2010 Dec 3. Int J Clin Pract. 2011. PMID: 21129135 Review.
Cited by
-
Antidepressants for the negative symptoms of schizophrenia.Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD005581. doi: 10.1002/14651858.CD005581.pub2. Cochrane Database Syst Rev. 2006. PMID: 16856105 Free PMC article.
-
Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.Cochrane Database Syst Rev. 2015 Jan 16;1(1):CD009831. doi: 10.1002/14651858.CD009831.pub2. Cochrane Database Syst Rev. 2015. PMID: 25592299 Free PMC article.
-
Haloperidol versus chlorpromazine for schizophrenia.Cochrane Database Syst Rev. 2008 Jan 23;2008(1):CD004278. doi: 10.1002/14651858.CD004278.pub2. Cochrane Database Syst Rev. 2008. PMID: 18254045 Free PMC article.
-
Haloperidol versus placebo for schizophrenia.Cochrane Database Syst Rev. 2013 Nov 15;2013(11):CD003082. doi: 10.1002/14651858.CD003082.pub3. Cochrane Database Syst Rev. 2013. PMID: 24242360 Free PMC article.
-
Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).Cochrane Database Syst Rev. 2017 Jul 31;7(7):CD009377. doi: 10.1002/14651858.CD009377.pub3. Cochrane Database Syst Rev. 2017. PMID: 28758203 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources